Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 8—August 2005

Dispatch

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table 2

Cost-benefit ratios of antiviral utilization strategies*

Strategy Cost-benefit ratio, relative to nonintervention
All costs to economy Direct healthcare costs
NI No intervention (base case) Ref. Ref.
1a Therapeutic use (all patients) 2.44 0.30
1b Therapeutic use (limited to patients at high risk) 3.68 1.51
2a Preexposure long-term prophylaxis of entire population 0.38 0.04
2b Preexposure long-term prophylaxis, limited to high-risk population 0.37 0.10
3a Postexposure short-term prophylaxis for all close contacts ("ring prophylaxis"), including treatment of index patients 2.49 0.27

*Ref., reference value of zero divided by zero.

Main Article

TOP